EFFECTS OF AN EIGHT-WEEK ATORVASTATIN TREATMENT ON SPONTANEOUS CYTOKINE PRODUCTION BY THE BLOOD MONONUCLEAR LEUKOCYTES IN METABOLIC SYNDROME
https://doi.org/10.15789/1563-0625-2014-5-481-186
Abstract
The aim of this study was to assess effects of the eight-week course of atorvastatin therapy upon the levels of spontaneous cytokine production by mononuclear blood leukocytes (MNBC) in metabolic syndrome. An open-label prospective study included 36 patients with stage II hypertension (blood pressure < 180/110 mm Hg.) accomplished by metabolic syndrome. Along with clinical surveys performed at a specialized cardiological clinics, we assessed spontaneous cytokine production by MNBC during treatment with atorvastatin. It was shown that the 8-week treatment of these patients with atorvaststin, at individually matched daily doses (20
to 40 mg) was associated with reduced serum concentration of acute phase proteins (C-reactive protein and neopterin), as well as decreased spontaneous production of proinflammatory cytokines (IL-1β, IL-6 and TNFα) by MNBCs. The latter finding is of great importance for pathogenesis of metabolic syndrome.
About the Authors
I. D. Bespalovа
Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
Russian Federation
Russian Federation
PhD, Head, Department of Social Work, Social and Clinical Psychology, Siberian State Medical University of Ministry of
Health of the Russian Federation 634050, Russian Federation, Tomsk, Moskovsky Tract, 2. Phone: 7 (903) 953-12-37
N. V. Ryazantseva
Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Head, Department of Molecular Medicine and Clinical Laboratory Diagnostics, Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
V. V. Kalyuzhin
Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Professor of Department of Hospital Therapy with a Course of Physical Rehabilitation and Sports Medicine, Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
B. Yu. Murashev
Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
Russian Federation
Russian Federation
Postgraduate Fellow, Department of Pathophysiology, Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
I. A. Osikhov
Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
Russian Federation
Russian Federation
Postgraduate Fellow, Department of Pathophysiology, Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
Yu. A. Medyantsev
Tomsk Central Regional Hospital, Tomsk, Russian Federation
Russian Federation
Physician, Tomsk Central Regional Hospital, Tomsk, Russian Federation
Russian Federation
Physician, Tomsk Central Regional Hospital, Tomsk, Russian Federation
D. S. Afanas’eva
Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
Russian Federation
Russian Federation
Resident Doctor, Siberian State Medical University of Ministry of Health of the Russian Federation, Tomsk, Russian Federation
References
1. Атрощенко Е.С. Плейoтропные эффекты статинов: новый аспект действия ГМК – КоА-редуктазы // Медицинские новости. 2004. № 3. С. 59-66. [Atroshchenko E.S. Pleyotropnye effekty statinov: novyy aspekt deystviya GMK – KoA-reduktazy [Pleiotropic effects of statins: a new aspect of the action of HMG – CoA reductase]. Meditsinskie novosti = Medical News, 2004, no. 3, pp. 59-66].
2. Беспалова И.Д., Медянцев Ю.А., Калюжин В.В., Мурашев Б.Ю., Осихов И.А. Качество жизни больных гипертонической болезнью с метаболическим синдромом // Артериальная гипертензия. 2012. Т. 18, № 4. С. 304-309. Bespalova I.D., Medyantsev Yu.A., Kalyuzhin V.V., Murashev B.Yu., Osikhov I.A. Kachestvo zhizni bol`nykh gipertonicheskoy bolezn`yu s metabolicheskim sindromom [The quality of life patients with hypertensive disease with metabolic syndrome]. Arterial`naya gipertenziya = Arterial Hypertension, 2012, Vol. 18, no. 4, pp. 304- 309].
3. Беспалова И.Д., Калюжин В.В., Медянцев Ю.А. Качество жизни больных ишемической болезнью сердца: взаимосвязь с компонентами метаболического синдрома и маркерами системного воспаления // Бюллетень сибирской медицины, 2012. № 6. С. 17-20. [Bespalova I.D., Medyantsev Yu.A., Kalyuzhin V.V. Kachestvo zhizni bol`nykh ishemicheskoy bolezn`yu serdtsa: vzaimosvyaz` s komponentami metabolicheskogo sindroma i markerami sistemnogo vospaleniya [Quality of life in patients with coronary heart disease: the relationship with the components of the metabolic syndrome and markers of systemic inflammation]. Byulleten` sibirskoy meditsiny = Bulletin of the Siberian Medicine, 2012, no. 6, pp. 17-20].
4. Беспалова И.Д., Калюжин В.В., Рязанцева Н.В., Медянцев Ю.А., Мурашев Б.Ю., Осихов И.А. Влияние 8-недельной терапии аторвастатином на качество жизни больных гипертонической болезнью с метаболическим синдромом // Артериальная гипертензия. 2013. Т. 19, № 2. С. 125-131. [Bespalova I.D., Kalyuzhin V.V., Ryazantseva N.V., Medyantsev Yu.A., Murashev B.Yu., Osikhov I.A. Vliyanie 8-nedel`noy terapii atorvastatinom na kachestvo zhizni bol`nykh gipertonicheskoy bolezn`yu s metabolicheskim sindromom [Influence of 8 weeks of treatment with atorvastatin on the quality of life of hypertensive patients with metabolic syndrome]. Arterial`naya gipertenziya = Arterial Hypertension, 2013, Vol. 19, no. 2, pp. 125-131].
5. Беспалова И.Д., Рязанцева Н.В., Калюжин В.В., Афанасьева Д.С., Мурашев Б.Ю., Осихов И.А. Системное воспаление в патогенезе метаболического синдрома и ассоциированных с ним заболеваний // Сибирский медицинский журнал (Иркутск). 2013. № 2. С. 5-9. [Bespalova I.D., Ryazantseva N.V., Kalyuzhin V.V., Afanas`eva D.S., Murashev B.Yu., Osikhov I.A. Sistemnoe vospalenie v patogeneze metabolicheskogo sindroma i assotsiirovannykh s nim zabolevaniy [Systemic inflammation in the pathogenesis of the metabolic syndrome and its associated diseases]. Sibirskiy meditsinskiy zhurnal (Irkutsk) = Siberian Medical Journal (Irkutsk), 2013, no. 2, pp. 5-9].
6. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации IV пересмотр. Всероссийское научное общество кардиологов.М., 2010. 88 с. [Diagnostika i korrektsiya narusheniy lipidnogo obmena s tsel`yu profilaktiki i lecheniya ateroskleroza. Rossiyskie rekomendatsii IV peresmotr. Vserossiyskoe nauchnoe obshchestvo kardiologov [Diagnosis and correction of disorders of lipid metabolism in the prevention and treatment of atherosclerosis. Russian Recommendation IV revision. All-Russian Scientific Society of Cardiology]. Moscow, 2010. 88 p.]
7. Драпкина О.М., Корнеева О.Н., Палаткина Л.О. Адипокины и сердечно-сосудистые заболевания: патогенетические параллели и терапевтические эффекты // Артериальная гипертензия. 2011. Т. 17,
8. № 3. С. 203-208. [Drapkina O.M., Korneeva O.N., Palatkina L.O. Adipokiny i serdechno-sosudistye zabolevaniya: patogeneticheskie paralleli i terapevticheskie effekty [Adipokines and cardiovascular diseases: pathogenetical parallels and therapeutic effects]. Arterial`naya gipertenziya = Arterial Hypertension, 2011, Vol. 17, no. 3, pp. 203-208].
9. Дружинина Ю.Г., Рыжикова С.Л., Рябичева Т.Г., Вараксин Н.А. Определение уровней спонтанной и митоген-индуцированной продукции цитокинов здоровых доноров ex vivo // Медицинская иммунология. 2009. Т. 11, № 4-5. С. 473. [Druzhinina Yu.G., Ryzhikova S.L., Ryabicheva T.G., Varaksin N.A. Opredelenie urovney spontannoy i mitogen-indutsirovannoy produktsii tsitokinov zdorovykh donorov ex vivo [Determination of the spontaneous and mitogen-induced cytokine production by healthy donors ex vivo]. Meditsinskaya immunologiya = Medical Immunology, 2009, Vol. 11, no. 4-5, pp. 473].
10. Инжутова А.И. Статины снижают дисфункцию эндотелия // Актуальные вопросы болезней сердца и сосудов. 2009. Т. 4, № 2. С. 61-66. [Inzhutova A.I. Statiny snizhayut disfunktsiyu endoteliya [Statins reduce endothelium dysfunction]. Aktual`nye voprosy bolezney serdtsa i sosudov = Actual Problems of Diseases of the Heart and Vessels, 2009, Vol. 2, no. 2, pp. 61-66].
11. Калюжин В.В., Тепляков А.Т., Рязанцева Н.В., Беспалова И.Д., Камаев Д.Ю., Калюжина Е.В. Качество жизни больных ишемической болезнью сердца, ассоциированной с метаболическим синдромом: результаты факторного анализа // Терапевтический архив. 2012. № 12. С. 18-22. [Kalyuzhin V.V., Teplyakov A.T., Ryazantseva N.V., Bespalova I.D., Kamaev D.Yu., Kalyuzhina E.V. Kachestvo zhizni bol`nykh ishemicheskoy bolezn`yu serdtsa, assotsiirovannoy s metabolicheskim sindromom: rezul`taty faktornogo analiza [Quality of life in patients with coronary heart disease associated with the metabolic syndrome: results of the factor analysis]. Terapevticheskiy arkhiv = Therapeutic Archive, 2012, no. 12, pp. 18-22].
12. Клинические рекомендации европейского общества кардиологов. М., 2008. 186 с. [Klinicheskie rekomendatsii evropeyskogo obshchestva kardiologov [Clinical practice guidelines of the European Society of Cardiology]. Moscow, 2008. 186 p.]
13. Маколкин В.И. Метаболический синдром. М.: Медицинское информационное агентство, 2010. 144 c. [Makolkin V.I. Metabolicheskiy sindrom [The metabolic syndrome]. Moscow: Medical Information Agency, 2010, 144 p.]
14. Мычка В.Б., Жернакова Ю.В., Чазова И.Е. Рекомендации экспертов Всероссийского общества кардиологов по диагностике и лечению метаболического синдрома (второй пересмотр). М.: Доктор. Ру, 2010. 18 с. Mychka V.B., Zhernakova Yu.V., Chazova I.E. Rekomendatsii ekspertov Vserossiyskogo obshchestva kardiologov po diagnostike i lecheniyu metabolicheskogo sindroma (vtoroy peresmotr) [Recommendations of the experts of the Russian Society of Cardiology on the diagnosis and treatment of the metabolic syndrome (second revision)]. Moscow: Doctor.Ru, 2010. 18 p.]
15. Силонова А.А., Барбараш О.Л., Акбашева О.Е., Паличева Е.И., Каретникова В.Н., Учасова Е.Г., Квиткова Л.В., Кашталап В.В., Груздева О.В. Влияние аторвастатина на липидтранспортную функцию крови, маркеры инсулинорезистентности и показатели воспаления у пациентов с инфарктом миокарда в динамике госпитального периода // Сердце: журнал для практикующих врачей. 2012. Т. 11, № 6. С. 330-336. [Silonova A.A., Barbarash O.L., Akbasheva O.E., Palicheva E.I., Karetnikova V.N., Uchasova E.G., Kvitkova L.V., Kashtalap V.V., Gruzdeva O.V. Vliyanie atorvastatina na lipidtransportnuyu funktsiyu krovi, markery insulinorezistentnosti i pokazateli vospaleniya u patsientov s infarktom miokarda v dinamike gospital`nogo perioda [Effect of atorvastatin on lipid-transport function of blood markers of insulin resistance and markers of inflammation in patients with myocardial infarction in the dynamics of hospital period]. Serdtse: zhurnal dlya praktikuyushchikh vrachey = Heart: Journal for Practicing Physicians, 2012, Vol. 11, no. 6, pp. 330-336].
16. Тотолян А.А., Балдуева И.А., Бубнова Л.Н. Стандартизация иммунофенотипирования крови и костного мозга человека // Клиническая лабораторная диагностика. 2002. № 1. С. 44-50. [Totolyan A.A., Baldueva I.A., Bubnova L.N. Standartizatsiya immunofenotipirovaniya krovi i kostnogo mozga cheloveka [Standardization of immunophenotyping of human blood and bone marrow]. Klinicheskaya laboratornaya diagnostika = Clinical Laboratory Diagnostics, 2002, no. 1, pp. 44-50].
17. Ширинский И.В., Ширинский В.С. Прогнозирование клинической эффективности лечения симвастатином у больных ревматоидным артритом // Медицинская иммунология. 2009. Т. 11, № 2-3. С. 221-226. [Shirinskiy I.V., Shirinskiy V.S. Prognozirovanie klinicheskoy effektivnosti lecheniya simvastatinom u bol`nykh revmatoidnym artritom [Predicting the clinical efficacy of treatment with simvastatin in patients with rheumatoid arthritis]. Meditsinskaya immunologiya = Medical Immunology, 2009, Vol. 11, no. 2-3, pp. 221-226].
18. Blaschke S., Viereck V., Schwarz G., Klinger H.M., Guerluek S., M ller G.A. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand. J. Rheumatol., 2009, Vol. 38, no. 4, pp. 235-239.
19. Gupta A., Badyal D.K, Khosla P.P., Uppal B., Jaison T.M., Chopra S. Effect of atorvastatin on hs‑CRP in acute coronary syndrome. Br. J. Clin. Pharmacol., 2008, Vol. 66, no. 3, pp. 411-413.
20. Potenza M.V., Mechanick J.I. The metabolic syndrome: definition, global impact, and pathophysiology. Nutr. Clin. Pract., 2009, Vol. 24, no. 5, pp. 560-577.
Review
For citations:
Bespalovа I.D., Ryazantseva N.V., Kalyuzhin V.V., Murashev B.Yu., Osikhov I.A., Medyantsev Yu.A., Afanas’eva D.S. EFFECTS OF AN EIGHT-WEEK ATORVASTATIN TREATMENT ON SPONTANEOUS CYTOKINE PRODUCTION BY THE BLOOD MONONUCLEAR LEUKOCYTES IN METABOLIC SYNDROME. Medical Immunology (Russia). 2014;16(5):481-186. (In Russ.) https://doi.org/10.15789/1563-0625-2014-5-481-186
Views:
1090
Email this article 